Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $39.20 Consensus Target Price from Analysts

Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) have earned an average rating of “Buy” from the seven brokerages that are currently covering the company, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $39.20.

Several brokerages have weighed in on SYRE. Stifel Nicolaus lifted their price target on Spyre Therapeutics from $36.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. Wells Fargo & Company upgraded Spyre Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $12.00 to $35.00 in a research report on Friday, March 1st.

Spyre Therapeutics Stock Performance

Spyre Therapeutics stock opened at $34.89 on Tuesday. The stock has a market cap of $1.26 billion, a PE ratio of -0.46 and a beta of 2.88. The firm’s 50 day simple moving average is $35.15. Spyre Therapeutics has a 52 week low of $2.66 and a 52 week high of $47.97.

Spyre Therapeutics (NASDAQ:SYRE) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($2.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($1.80). Equities analysts forecast that Spyre Therapeutics will post -2.36 EPS for the current year.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).